Harvard Apparatus Regenerative Technology Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Harvard Apparatus Regenerative Technology Inc (BSTG) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Harvard Apparatus Regenerative Technology Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 1,374M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+2.1% annualized vs trailing 12 months), vs decelerating (-21.8%) for its tracked peer group.
- Growth: Harvard Apparatus Regenerative Technology Inc generated 402.2% revenue growth year over year in Q1 2026, vs 22.9% for its tracked competitors combined.
- Profitability: Its -708.4% net margin compares with -26.3% for the peer group.
- Peer revenue share: Harvard Apparatus Regenerative Technology Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.11M compares with $0.80M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BSTG Sales vs. its Competitors, Q1 2026
Harvard Apparatus Regenerative Technology Inc reported revenue growth of 402.22 % year on year in Q1 2026, above its competitors' combined revenue growth of 22.87 %.
With a net margin of -708.41 %, Harvard Apparatus Regenerative Technology Inc reported lower profitability than its competitors (-26.32 %).
Harvard Apparatus Regenerative Technology Inc generated 0.08 % of the combined sales of its peer group, up from 0.02 % a year earlier.
Harvard Apparatus Regenerative Technology Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Harvard Apparatus Regenerative Technology Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Harvard Apparatus Regenerative Technology Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Harvard Apparatus Regenerative Technology Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs 402.2% for Harvard Apparatus Regenerative Technology Inc. Harvard Apparatus Regenerative Technology Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Harvard Apparatus Regenerative Technology Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Harvard Apparatus Regenerative Technology Inc | - | Yes | Yes | Yes |
| Competitors combined (6) | ||||
| High-Confidence Competitors (11) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BSTG Stock Performance relative to its Competitors
BSTG Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Tarsus Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Vericel Corporation | 282.9% | Outperformed |
| 3 | Mesoblast Limited | 282.9% | Outperformed |
| 4 | Organogenesis Holdings Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Harvard Apparatus Regenerative Technology Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Harvard Apparatus Regenerative Technology Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Harvard Apparatus Regenerative Technology Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Harvard Apparatus Regenerative Technology Inc | 78.23 | 0.89 |
| Tarsus Pharmaceuticals Inc | 3,327.86 | 606.33 |
| Vericel Corporation | 2,124.39 | 306.30 |
| Mesoblast Limited | 1,795.99 | 17.20 |
| Organogenesis Holdings Inc | 178.21 | 457.45 |
| Vycor Medical Inc | 2.24 | 1.81 |
| SUBTOTAL | 7,507.31 | 1,391.66 |
Sign in to see all competitors of Harvard Apparatus Regenerative Technology Inc .
Sources: Harvard Apparatus Regenerative Technology Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Harvard Apparatus Regenerative Technology Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Harvard Apparatus Regenerative Technology Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Organogenesis | Named by the company | 85% |
| Tissue Genesis, Inc. | Named by the company | 85% |
| Caladrius Biosciences | Named by the company | 85% |
| Lineage Cell Therapeutics | Named by the company | 85% |
| Neuralstem | Named by the company | 85% |
| Pluristem | Named by the company | 85% |
| Vericel Corporation | Named by the company | 85% |
| Athersys | Named by the company | 85% |
| Humacyte | Named by the company | 85% |
| Miromatrix Medical | Named by the company | 85% |
| Organovo | Named by the company | 85% |
| Tissue Growth Technologies | Named by the company | 85% |
| Aldagen | Named by the company | 85% |
| Cytori Therapeutics | Named by the company | 85% |
| Mesoblast | Named by the company | 85% |
| Orgagen | Named by the company | 85% |
| Smiths Medical | Named by the company | 85% |
| W.L. Gore and Associates | Named by the company | 85% |
| BioTime | Named by the company | 85% |
| InVivo Therapeutics | Named by the company | 85% |
| Nanofiber Solutions | Named by the company | 85% |
| Osiris Therapeutics | Named by the company | 85% |
| United Therapeutics | Named by the company | 85% |
| Asterias Biotherapeutics | Named by the company | 85% |
| E. I. du Pont de Nemours and Company | Named by the company | 85% |
| Miramatrix Medical | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Harvard Apparatus Regenerative Technology Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Harvard Apparatus Regenerative Technology Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Harvard Apparatus Regenerative Technology Inc | Consumer Health Products 100.00 % |
| Tarsus Pharmaceuticals Inc | Reportable 100.00 % |
| Vycor Medical Inc | Vycor Medical Inc 95.93 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Harvard Apparatus Regenerative Technology Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology Inc | 78 | 110,625 | -851,375 |
| Tarsus Pharmaceuticals Inc | 3,328 | 1,638,732 | -125,611 |
| Vericel Corporation | 2,124 | 769,606 | 60,857 |
| Mesoblast Limited | 1,796 | 159,241 | -945,759 |
| Organogenesis Holdings Inc | 178 | 535,660 | -109,956 |
| Vycor Medical Inc | 2 | 258,210 | -8,561 |
| PEERS TOTAL | 7,429 | 796,096 | -128,899 |
Sign in to see all peers for Harvard Apparatus Regenerative Technology Inc .
Harvard Apparatus Regenerative Technology Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vycor Medical Inc | US 99.66 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Harvard Apparatus Regenerative Technology Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 222 companies in Harvard Apparatus Regenerative Technology Inc's industry classification, broader than the peer set above. Market cap in millions of $.Harvard Apparatus Regenerative Technology Inc ranks #0 of 222 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 589, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 147,097 | 13.40 % |
| 2 | Medtronic Plc | 113,821 | 10.37 % |
| 3 | Stryker Corp | 107,775 | 9.82 % |
| 4 | 3m Company | 89,163 | 8.12 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Dexcom Inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Alcon inc | 1,234 | 5.2% |
| 0 | Harvard Apparatus Regenerative Technology Inc | 78 | 0.00 % |
Market cap and industry share for the rest of Harvard Apparatus Regenerative Technology Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2023-07-20.
Harvard Apparatus Regenerative Technology Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (288 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 7.46 % | 53.36 % (avg) | -45.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.79 % (avg) | - |
| Capital Intensity (Capex / Revenue) | - | 5.43 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Harvard Apparatus Regenerative Technology Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | 63.72 % |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -342.18 % | -112.51 % | -331.56 % | -242.68 % | 254.05 % | -196.58 % | -208.18 % | -243.51 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Harvard Apparatus Regenerative Technology Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 589 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Harvard Apparatus Regenerative Technology Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Harvard Apparatus Regenerative Technology Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Harvard Apparatus Regenerative Technology Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+2.1% annualized vs trailing 12 months).
Weaknesses
- Return on equity 794.8 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-21.8% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Harvard Apparatus Regenerative Technology Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology Inc | 0.73 | 1.03 | 0.10 |
| Tarsus Pharmaceuticals Inc | 0.36 | 3.71 | 0.21 |
| Vericel Corporation | 2.24 | 5.03 | - |
| Mesoblast Limited | 1.57 | 1.99 | 0.09 |
| Organogenesis Holdings Inc | 0.91 | 3.50 | - |
| Vycor Medical Inc | 0.02 | 0.12 | - |
Sign in to see all peers for Harvard Apparatus Regenerative Technology Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Harvard Apparatus Regenerative Technology Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology Inc | Q1 2026 | +402.2 % | - |
| Tarsus Pharmaceuticals Inc | Q2 2026 | +69.4 % | - |
| Vericel Corporation | Q2 2026 | +22.5 % | - |
| Mesoblast Limited | Q2 2025 | +191.4 % | - |
| Organogenesis Holdings Inc | Q2 2026 | -56.7 % | - |
| Vycor Medical Inc | Q2 2026 | -15.7 % | - |
| PEERS TOTAL | +14.4 % | - |
Sign in to see all peers for Harvard Apparatus Regenerative Technology Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Harvard Apparatus Regenerative Technology Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology Inc | Q1 2026 | +524.2 % | - |
| Tarsus Pharmaceuticals Inc | Q2 2026 | +94.2 % | +306.5 % |
| Vericel Corporation | Q2 2026 | +26.6 % | -76.2 % |
| Mesoblast Limited | Q2 2025 | - | +150.9 % |
| Organogenesis Holdings Inc | Q2 2026 | - | -69.8 % |
| Vycor Medical Inc | Q2 2026 | -9.0 % | - |
Sign in to see all peers for Harvard Apparatus Regenerative Technology Inc .
Harvard Apparatus Regenerative Technology Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology Inc | - | - | - |
| Tarsus Pharmaceuticals Inc | - | - | - |
| Vericel Corporation | 5.02% | 5.58% | 6.91% |
| Mesoblast Limited | - | - | - |
| Organogenesis Holdings Inc | - | - | - |
| Vycor Medical Inc | - | - | - |
Sign in to see all peers for Harvard Apparatus Regenerative Technology Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Harvard Apparatus Regenerative Technology Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Harvard Apparatus Regenerative Technology Inc | - | 88.40 |
| Tarsus Pharmaceuticals Inc | - | 5.49 |
| Vericel Corporation | 86.40 | 6.94 |
| Mesoblast Limited | - | 104.43 |
| Organogenesis Holdings Inc | - | 0.39 |
| Vycor Medical Inc | - | 1.24 |
| PEERS AVERAGE | - | 5.39 |
Sign in to see all peers for Harvard Apparatus Regenerative Technology Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.